About

The Health 2030 Genome Center is a non-profit institution that promotes personalized health and genomic medicine by providing genomic services for clinical diagnostics and research.

Its services incorporate ISO 15189 accredited DNA and RNA sequencing as well as data analytics for clinical decision support and population genomics research.

Data generation services

Data generation services
  • Clinical grade whole genome sequencing (WGS)
  • Clinical grade whole exome sequencing (WES)
  • Clinical grade RNA sequencing (RNA-seq)
  • Fast turnaround time clinical grade WGS, WES and RNA-seq
  • Low-coverage WGS with variant imputation
  • Viral pathogen WGS
  • Microbiome WGS

Data analysis services

Data analysis services
  • Sequencing data processing
  • Genome variant calling
  • Variant clinical annotation and prioritizing
  • RNA expression profiling
  • Single cell RNA-seq
IMG_bg-01@3x
IMG_bg-02@3x

Clinical-grade, fast turnaround time WGS: From DNA to variant interpretation

Clinical-grade, fast turnaround time WGS: From DNA to variant interpretation
WGS_flow

The Health 2030 Genome Center is also part of the Swiss Multi-Omics Center (http://smoc.ethz.ch). This center combines expertise in genomics, transcriptomics, proteomics and metabolomics for the integrated multi-omic analysis of clinical specimens.

The Health 2030 Genome Center partners are the universities and university hospitals of Bern, Lausanne and Geneva and the Swiss Federal Institute of Technology Lausanne (UNIBE, Inselspital, UNIL, CHUV, UNIGE, HUG and EPFL).

TEAM

TEAM
JFellay
Jacques Fellay

Chief Science Officer

Jacques Fellay, MD PhD

Jacques Fellay is a medical doctor and researcher, with expertise in genomics and infectious diseases and strong interest in personalized health. He is the founding director of the Precision Medicine Unit of the Lausanne University Hospital (CHUV) and leads a genomics laboratory at the EPFL School of Life Sciences.

The aim of his research is to decipher the genetic basis of inter-individual differences in immunity and responses to infections.
His group explores the role of human genetic variation in the host-pathogen battle, in the hope of shedding new light on basic biological mechanisms, and of paving the way toward more personalized approaches to health.

He received multiple awards, including the National Latsis Prize in 2011 for his work on the genetic control of HIV and hepatitis C virus infections.

Full bio
CONTACT
KHarshman
Keith Harshman

Chief Operations Officer

Keith Harshman, PhD

Keith Harshman received a PhD in Biochemistry from the California Institute of Technology in 1990.Following post-doctoral fellowships at the Universityof Zurich and the Sloan-Kettering Cancer Center, in 1993 he joined Myriad Geneticswhere he workedfirst as a Senior Scientist and later as the Director of Central Nervous System Disease Research. In 1997 he moved to the Spanish National Biotechnology Center as the Head of the Functional Genomics Unit. In 2003 he joined the Center for Integrative Genomics at the University of Lausanne where he served as Coordinator of the Genomic Technologies Facility.He moved tothe Health 2030 Genome Center in December of 2017.

Full bio
CONTACT
Ioannis_Xenarios_portrait_UNil
Ioannis Xenarios

Chief Data Analytics Officer

Ioannis Xenarios, PhD

Ioannis Xenarios is a trained computational immunologist who received a PhD from the University of Lausanne and the Ludwig Institute for Cancer Research. During his study he taught bioinformatics and computational biology in the early days of bioinformatics to student in biochemistry. At the end of his PhD he moved to UCLA University of California Los Angeles where he worked on several comparative genomics and interactions databases to study complexity of cellular networks. He then moved to Serono (later bought by Merck into Merck-Serono) to lead the development in proteomics and genomics in both translational and early discovery. He then led the group of Vital-IT and Swiss-Prot at the SIB Swiss Institute of Bioinformatics for eleven years where he developed with his team methods in non invasive prenatal diagnostic, early biomarker discovery in diabetes, neo-antigen, systems immunology in cancer biology, integrative biology and proteogenomics approaches.
He is also a professor of computational biology and bioinformatics at the University of Lausanne and a Professeur titulaire at the University of Geneva.

He has now a secondment at the Genome Center to develop and lead the establishment of the Data Analytics and Interpretation Platform.

Ioannis Xenarios served on several national and international body (ESFRI, IMI-JU, FRM and several computational and non-computational journals).

Full bio
CONTACT
2020_09_08_2482
Petros Tsantoulis

Chief Medical Officer

Petros Tsantoulis, MD, PhD

Petros Tsantoulis obtained his medical degree from the University of Athens, Greece, in 2003. He completed his doctoral thesis in 2007 at the same university under the supervision of Prof Vassilis Gorgoulis studying the genome-wide distribution of double-strand breaks in models of cancer. Petros Tsantoulis came to Geneva to work at the HUG where he was trained as a specialist in both Internal Medicine and Oncology. Since 2011 he has been working in the Department of Medical Oncology, where he co-founded the Molecular Tumorboard in 2016. His research focus is motivated by his interest in precision oncology and involves the development of biomarkers that can inform cancer prognosis and predict response to treatment, and the recognition of clinically meaningful disease subtypes. Petros Tsantoulis maintains a clinical activity focused on urogenital tumors.

Full bio
CONTACT
ProfilePicture_KM_crop
Katrin Männik

Head of Genomics Strategy

Katrin Männik, PhD

Katrin Männik was trained in biomedicine, molecular diagnostics and gene technology. She received a PhD from the University of Tartu in 2012. Following post-doctoral training at the Center for Integrative Genomics at the University of Lausanne, she worked as a Research Associate at the University of Lausanne and at the Estonian Genome Center (Estonian population-based biobank). She joined the Health 2030 Genome Center in November 2019.

Her research, supported by the European Commission, the Swiss National Science Foundation and the Jacobs Foundation, has been mainly focused on genetic variants underlying neurodevelopmental disorders and variability of complex traits in the population.

She has authored and co-authored numerous studies published in the top scientific and medical journals (e.g. JAMA, Nature, Am J Hum Genet), and presented platform talks in main international scientific conferences in the field of human genetics and personalized medicine.  

Besides basic research she has a longtime interest in translational and ethical aspects related to the usage of genetic data in healthcare. Katrin Männik has been participating in various initiatives aiming to reach out to the medical community and to society. She is actively involved in national and international projects that work towards maximizing the impact of research and setting the ground for the emergence of personalized medicine. 

Full bio
CONTACT
HOWALD_IMG_8027
Cédric Howald

Head of the DNA Sequencing Platform

Cédric Howald, PhD

Full bio
CONTACT
DNA Sequencing Platform Team
Data Analytics and Interpretation Platform Team
Science Council

news & events

news & events
05.12.2024

Professor Alexandre Reymond Appointed New Director

Geneva, Switzerland – December 04, 2024 – The Health 2030 Genome Center, a leading hub for genomic…

,
07.05.2024

Meet the Genome Center in Berlin at the European Society of Human Genetics!  

The annual meeting of the European Society of Human Genetics (ESHG) brings together scientists and health care…

21.09.2023

Genomic medicine gets closer to the clinic

The Health 2030 Genome Center (Genome Center) has obtained a major accreditation extension for human genome sequencing…

VIEW ALL NEWS & EVENTS

To stay informed of our news, register to join our distribution list 

Subscribe to our mailing list

* indicates required






REGISTER